Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss for the six months ended 30 June 2025 and 2024

|  |
| --- |
|  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| *USD in thousands, except for per share amounts* |  | **Six months ended 30 June 2025** |  | **Six months ended 30 June 2024** |  |
| Product revenue |  |  204,733  |  |  65,912  |  |
| License and other revenue |  |  101,271  |  |  169,678  |  |
| Other income |  |  143  |  |  57  |  |
| Cost of product revenue |  |  (139,272) |  |  (65,167) |  |
| Research and development expenses |  |  (92,889) |  |  (97,479) |  |
| General and administrative expenses |  |  (45,347) |  |  (29,554) |  |
| **Operating profit** |  |  28,639  |  |  43,447  |  |
| Loss on sale of interest in joint venture |  |  —  |  |  (2,970) |  |
| Finance income |  |  149,247  |  |  80,823  |  |
| Finance costs |  |  (72,190) |  |  (277,414) |  |
| Exchange rate differences |  |  (19,683) |  |  7,742  |  |
| Gain on modification and extinguishment of financial liabilities |  |  16,718  |  |  —  |  |
| **Non-operating profit / (loss)** |  |  74,092  |  |  (191,819) |  |
| **Profit / (loss) before taxes** |  |  102,731  |  |  (148,372) |  |
| Income tax benefit / (expense) |  |  38,987  |  |  (5,132) |  |
| **Profit / (loss) for the period** |  |  141,718  |  |  (153,504) |  |
| **Other comprehensive profit / (loss)** |  |  |  |  |  |
| *Item that will be reclassified to profit or loss in subsequent periods:* |  |  |  |  |  |
| Exchange rate differences on translation of foreign operations |  |  3,434  |  |  121  |  |
| **Total comprehensive profit / (loss)** |  |  145,152  |  |  (153,383) |  |
| **Profit / (loss) per share** |  |  |  |  |  |
| Basic profit / (loss) for the period per share |  |  0.50  |  |  (0.61) |  |
| Diluted profit / (loss) for the period per share |  |  0.49  |  |  (0.61) |  |

Unaudited Condensed Consolidated Interim Statements of Financial Position as of 30 June 2025 and 31 December 2024

|  |
| --- |
|  |

*USD in thousands*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Non-current assets** |  | **30 June** **2025** |  | **31 December** **2024** |
| Property, plant and equipment |  |  306,596  |  |  284,546  |
| Right-of-use assets |  |  134,481  |  |  125,198  |
| Goodwill |  |  12,790  |  |  11,330  |
| Other intangible assets |  |  54,688  |  |  20,621  |
| Contract assets |  |  32,070  |  |  22,710  |
| Other long-term assets |  |  4,338  |  |  3,615  |
| Deferred tax assets |  |  338,330  |  |  298,360  |
| **Total non-current assets** |  |  883,293  |  |  766,380  |
| **Current assets** |  |  |  |  |
| Inventories |  |  155,490  |  |  127,889  |
| Trade receivables |  |  108,103  |  |  160,217  |
| Contract assets |  |  46,664  |  |  67,304  |
| Other current assets |  |  47,579  |  |  48,064  |
| Receivables from related parties |  |  173  |  |  118  |
| Cash and cash equivalents |  |  151,452  |  |  51,428  |
| **Total current assets** |  |  509,461  |  |  455,020  |
| **Total assets** |  |  1,392,754  |  |  1,221,400  |

Unaudited Condensed Consolidated Interim Statements of Financial Position as of 30 June 2025 and 31 December 2024

|  |
| --- |
|  |

*USD in thousands*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Equity** |  | **30 June** **2025** |  | **31 December** **2024** |
| Share capital |  |  2,924  |  |  2,826  |
| Share premium |  |  2,102,896  |  |  2,007,058  |
| Other reserves |  |  15,627  |  |  17,272  |
| Translation reserve |  |  1,216  |  |  (2,218) |
| Accumulated deficit |  |  (2,295,991) |  |  (2,437,709) |
| **Total equity** |  |  (173,328) |  |  (412,771) |
| **Non-current liabilities** |  |  |  |  |
| Borrowings |  |  1,072,138  |  |  1,035,882  |
| Derivative financial liabilities |  |  63,004  |  |  210,224  |
| Lease liabilities |  |  136,263  |  |  112,137  |
| Contract liabilities |  |  12,914  |  |  80,721  |
| Deferred tax liability |  |  2,014  |  |  1,811  |
| **Total non-current liabilities** |  |  1,286,333  |  |  1,440,775  |
| **Current liabilities** |  |  |  |  |
| Trade and other payables |  |  84,282  |  |  67,126  |
| Lease liabilities |  |  13,591  |  |  9,515  |
| Current maturities of borrowings |  |  46,026  |  |  32,702  |
| Liabilities to related parties |  |  1,641  |  |  8,465  |
| Contract liabilities |  |  60,333  |  |  15,980  |
| Taxes payable |  |  741  |  |  204  |
| Other current liabilities |  |  73,135  |  |  59,404  |
| **Total current liabilities** |  |  279,749  |  |  193,396  |
| **Total liabilities** |  |  1,566,082  |  |  1,634,171  |
| **Total equity and liabilities** |  |  1,392,754  |  |  1,221,400  |

Unaudited Condensed Consolidated Interim Statements of Cash Flows for the six months ended 30 June 2025 and 2024

|  |
| --- |
|  |

*USD in thousands*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cash flows from operating activities** |  | **Six months ended 30 June 2025** |  | **Six months ended 30 June 2024** |
| Profit (loss) for the period |  |  141,718  |  |  (153,504) |
| **Adjustments for non-cash items:** |  |  |  |  |
| Depreciation and amortization |  |  17,156  |  |  14,748  |
| Change in inventory reserves |  |  5,238  |  |  (6,936) |
| Change in allowance for receivables |  |  703  |  |  —  |
| Share-based payments |  |  3,418  |  |  5,294  |
| Loss on sale of interest in joint venture |  |  —  |  |  2,970  |
| Gain on modification and extinguishment of financial liabilities |  |  (16,718) |  |  —  |
| Finance income |  |  (149,247) |  |  (80,823) |
| Finance costs |  |  72,190  |  |  277,414  |
| Exchange rate difference |  |  19,683  |  |  (7,742) |
| Income tax benefit |  |  (38,987) |  |  5,132  |
| **Operating cash flow before movement in working capital** |  |  55,154  |  |  56,553  |
| Increase in inventories |  |  (32,839) |  |  (15,205) |
| Decrease / (increase) in trade receivables |  |  51,411  |  |  (52,229) |
| (Increase) / decrease in receivables with related parties |  |  (55) |  |  92  |
| Decrease / (increase) in contract assets |  |  13,624  |  |  (27,179) |
| (Increase) / decrease in other assets |  |  (990) |  |  369  |
| Increase / (decrease) in trade and other payables |  |  17,757  |  |  (21,758) |
| Decrease in contract liabilities |  |  (31,743) |  |  (35,881) |
| (Decrease) / increase in liabilities with related parties |  |  (3,917) |  |  16,677  |
| Increase / (decrease) in other liabilities |  |  8,127  |  |  (6,056) |
| **Cash from (used in) operations** |  |  76,529  |  |  (84,617) |
| Interest received |  |  50  |  |  26  |
| Interest paid |  |  (8,039) |  |  (41,037) |
| Income tax paid |  |  (249) |  |  (372) |
| **Net cash from (used in) operating activities** |  |  68,291  |  |  (126,000) |
| **Cash flows from investing activities** |  |  |  |  |
| Acquisition of property, plant and equipment |  |  (36,805) |  |  (10,271) |
| Acquisition of intangible assets |  |  (15,168) |  |  (1,430) |
| Restricted cash in connection with amended bond agreement |  |  —  |  |  1,132  |
| Proceeds from the sale in joint venture |  |  2,975  |  |  —  |
| **Net cash used in investing activities** |  |  (48,998) |  |  (10,569) |
|  |  |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Cash flows from financing activities** |  | **Six months ended 30 June 2025** |  | **Six months ended 30 June 2024** |
| Repayments of borrowings |  |  (7,757) |  |  (75,059) |
| Repayments of principal portion of lease liabilities |  |  (4,924) |  |  (4,815) |
| Proceeds from new borrowings |  |  11,267  |  |  67,500  |
| Gross proceeds from equity offering |  |  82,481  |  |  150,451  |
| Fees from equity offering |  |  (3,759) |  |  (5,812) |
| Proceeds from warrants |  |  —  |  |  4,841  |
| Stock options exercised |  |  —  |  |  76  |
| **Net cash generated from financing activities** |  |  77,308  |  |  137,182  |
| Increase in cash and cash equivalents |  |  96,601  |  |  613  |
| Cash and cash equivalents at the beginning of the year |  |  51,428  |  |  11,157  |
| Effect of movements in exchange rates on cash held |  |  3,423  |  |  (826) |
| **Cash and cash equivalents at the end of the period** |  |  151,452  |  |  10,944  |